Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

IntroductionRadium-223 dichloride (Ra-223) is recommended as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and no visceral disease, after docetaxel failure, or in patients who are not candidates to receive it. In this study,...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Urbano Anido-Herranz, Ovidio Fernandez-Calvo, Juan Ruiz-Bañobre, Sara Martinez-Breijo, Natalia Fernandez-Nuñez, Zulema Nogareda-Seoane, Miguel Garrido-Pumar, Javier Casas-Nebra, Gloria Muñiz-Garcia, Paula Portela-Pereira, Antonio Gomez-Caamaño, Daniel Adolfo Perez-Fentes, Lucia Santome-Couto, Martín Lázaro, Aurea Molina-Diaz, Ana Medina-Colmenero, Sergio Vazquez-Estevez
Format:	Artigo
Sprog:	Inglês
Udgivet:	Frontiers Media S.A. 2024-05-01
Serier:	Frontiers in Oncology
Fag:	metastatic castration-resistant prostate cancer Radium-223 alkaline phosphatase bone health agents real-world data
Online adgang:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1385466/full
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!